U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459608) titled 'Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma' on March 05.
Brief Summary: This is a multicenter, prospective, single-arm phase II study designed to evaluate the safety and efficacy of lisaftoclax (APG-2575), an oral selective BCL-2 inhibitor, in patients with indolent B-cell lymphomas. The study will enroll adult patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), or marginal zone lymphoma (MZL) who are either treatment-naive but considered ineligible for Bruton tyrosine kinase (BTK) inhibitor therapy due to significant comorbidities, or who are intol...